MetaCap

Genelux (GNLX) vs Jyong Biotech (MENS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Genelux (GNLX) has outperformed Jyong Biotech (MENS) over the past year, losing 56.3% versus a loss of 95.3%. Jyong Biotech is the larger company by market cap ($110.2 million vs $103.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GNLX-56.25%MENS-95.28%
+21%-40%-101%
Nov 21, 20251 yearNov 20, 2026
GNLX-26.94%MENS-81.90%
+759%+319%-122%
Jun 16, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GNLX versus MENS key metrics
MetricGNLXMENS
Share price$2.17$1.45
Market cap$103.36M$110.24M
1-day change-4.82%-17.14%
YTD return-50.23%-63.29%
1-year return-56.25%-95.28%
EPS (TTM)$-0.88$-0.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.00K—
Revenue growth (YoY)0.00%—
Net income (latest FY)$-32.15M$-4.67M
Operating margin-415175.00%—
Net margin-401812.50%—
52-week high$5.89$38.88
52-week low$1.77$1.43
Distance from 52-week high-63.16%-96.27%
Analyst consensusstrong_buy—
Avg. price target upside+767.74%—
Average volume333.31K44.23K
Shares outstanding47.63M74.23M
Employees2527
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GNLX has outperformed MENS by 39.0 percentage points over the past year.

About Genelux

GNLX stock →

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

About Jyong Biotech

MENS stock →

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

GNLX vs MENS FAQ

Which is bigger, Genelux or Jyong Biotech?

Jyong Biotech (MENS) is larger, with a market capitalization of $110.24M compared with $103.36M for Genelux (GNLX).

Which stock has performed better over the past year, GNLX or MENS?

GNLX returned -56.25% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.

Are Genelux and Jyong Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons